All In Biotech

Drug Trial Radar · NCT05741710

A Study to Assess the Use of Methylone in the Treatment of PTSD

A Pilot Study to Assess the Use of Methylone in the Treatment of PTSD IMPACT-1 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

79

Actual

Start

Mar 1, 2023

Primary completion

Feb 19, 2025

Study completion Feb 19, 2025

Sponsor

Lead sponsor
Transcend TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is evaluating the safety, tolerability, and efficacy of methylone in adults with PTSD. The study will be conducted in two parts. * Part A is open-label and will enroll up to 15 participants with PTSD * Part B is randomized (1:1), double-blind, placebo-controlled and will enroll up to 64 participants with PTSD Eligible participants will enter a 4-week Treatment Period where they will receive methylone once weekly for 4 weeks (4 treatment sessions). Following the Treatment Period, participants will enter a 6-week Follow-up Period which includes 3 reflection visits (Week 4, 5, and 6) and a final study visit at Week 10.

Conditions

  • Post Traumatic Stress Disorder

Interventions

  • MethyloneDrug

    Methylone capsules, given orally, once a week for 4 weeks

  • PlaceboDrug

    Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in CAPS-5 Total Severity ScoreTime frame: up to 10 weeks

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Mountain View Clinical Research

    Denver, Colorado

  • Clinical Neuroscience Solutions - Jacksonville

    Jacksonville, Florida

  • Accel Research Sites

    Maitland, Florida

  • Sunstone Therapies

    Rockville, Maryland

  • Boston Clinical Trials

    Boston, Massachusetts

  • Cenexel HRI

    Berlin, New Jersey

  • The Rivus Wellness & Research Institute

    Oklahoma City, Oklahoma

  • Cedar Clinical Research

    Murray, Utah

  • Tallaght Adult Mental Health Services

    Dublin, Ireland

  • La Nua Day Hospital Mental Health Centre

    Galway, Ireland

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Glasgow Clinical Research Facility, QEUH

    Glasgow, United Kingdom

  • Clerkenwell Health

    London, United Kingdom

  • King's College

    London, United Kingdom

  • Oxford Health NHS Foundation Trust

    Oxford, United Kingdom

  • Mirabilis Health

    Belfast, Northern Ireland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.